PREVENTION OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS

Size of the Problem and Mechanisms of Control

Bluegrass Community Health Coalition
March 28, 2014

Kevin T. Kavanagh, MD, MS
Health Watch USA

The information in this presentation is the express opinion of Kevin T Kavanagh
Many Healthcare Associated Infections are Multi-Resistant Drug Organisms

- Affects 1 in 25 Hospitalized Patients
- Top 10 Cause of Death in the United States

Nationally, deaths from HAIs equal more than one Boeing 767 crashing every day.

Healthcare Associated Infections

- In the USA -- HAIs just in Hospitals cost 30 Billion Dollars Annually.
- In Kentucky - - An annual cost of almost 400 million dollars & almost 1400 lives lost from 23,000 HAIs.
HAIs a System Wide Problem

<table>
<thead>
<tr>
<th>Type of Facility</th>
<th>Number in Kentucky</th>
</tr>
</thead>
<tbody>
<tr>
<td>Long Term Care Facilities</td>
<td>307</td>
</tr>
<tr>
<td>Hospitals (Not Critical Access)</td>
<td>94</td>
</tr>
<tr>
<td>Critical Access Hospitals</td>
<td>29</td>
</tr>
<tr>
<td>Surgery Centers</td>
<td>31</td>
</tr>
<tr>
<td>Dialysis Centers</td>
<td>57</td>
</tr>
</tbody>
</table>

Acute care facilities comprise less than 20% of the facilities in Kentucky.
One Facility Can Affect Rates In Another Facility (Nursing Homes or Hospitals)


- “Our simulation demonstrated that each hospital's decision to test for MRSA and implement contact isolation procedures could affect the MRSA prevalence in all other hospitals.” Health Affairs 2012 PMID: 23048111 http://www.ncbi.nlm.nih.gov/pubmed/23048111


MDROs Significance & HAIs

- MDRO - Defined as non-susceptibility to at least one agent in three or more antimicrobial categories

From the CDDEP – HW USA Presentation, Samanth Gandra, March 16, 2014
Most common HAI Bacteria – CDC Mar. 26, 2014:
- C. difficile (12%),
- Staphylococcus aureus, including MRSA (11%),
- Klebsiella (10%),
- E. coli (9%),
- Enterococcus (9%), and
- Pseudomonas (7%).

Klebsiella and E. coli are members of the Enterobacteriaceae bacteria family, which has become increasingly resistant to last-resort antibiotics known as carbapenems.
Infections from MDROs have twice the mortality rate as other Healthcare Associated Infections (HAIs)

The percentage of these infections is growing.

From the CDDEP – HW USA Presentation, Samanth Gandra, March 16, 2014
Thus, if left unchecked has the potential of doubling the mortality rate for HAI.
MRSA – How Are We Doing

Invasive MRSA Cases

- 59% Hospital-onset
- 27% Healthcare-associated, community onset (HACO)
- 13% Community-associated
- 1% indeterminate

Remember 85% of MRSA infections are Healthcare Associated.
HP2020 HAI Webinar - Aug. 16, 2011
Methicillin-Resistant Staphylococcus Aureus - MRSA

Proportion of MRSA among S. aureus blood isolates in Europe and North America - 2012

From the CDDEP – HW USA Presentation, Samanth Gandra, March 16, 2014
In Northern Europe – Less than 5% of Staph Cultures are MRSA Positive.

In the United States – 50% of Staph Cultures are MRSA Positive.

In the Region Kentucky Resides – Almost 70% of Staph Cultures are MRSA Positive.
Data conflicting on meeting goals – No Uniform Reporting System:

- Emerging Infections Program (EIP) (JAMA, 2010, 2013) – Yes {Overall 21% decrease, Hospital Onset a 46% decrease}
- Healthcare Cost and Utilization Project (H-Cup Data) (USA Today, Dec 2013) – No {460,000 Hospitalizations involving MRSA, 23,000 Deaths}
- University Healthsystem Consortium (UHC) (ICHE, 2013) – No “The number of hospital admissions for any MRSA infection per 1,000 hospital admissions overall increased during 2003–2008”
- NHSN (Dept. HHS, 2014) – No {Data from 1/1/2013 to 3/31/2013: SIR is 1.05, Base Data 2010}
- Pediatric Survey (Pediatrics, 2013) – No “there were no significant reductions in health care-associated MRSA infections in children.”
MRSA – Reporting Requirements

- MRSA is reported for bloodstream infections (lab event).
  -- The picture to the right would not be reportable.
# MRSA Infection Reduction

<table>
<thead>
<tr>
<th>Reduction In MRSA Infections (Interventions which use surveillance)</th>
<th>No Effect on MRSA Infections (Interventions which do not use surveillance)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Almost 40 other studies.</td>
<td></td>
</tr>
</tbody>
</table>
Reduction Associated With Surveillance

Well Controlled Study. MRSA decreased by:
-- 36.2% from baseline to ICU Surveillance.
-- 69.6% from baseline to Universal Surveillance.
To the right is a drop in MRSA bacteremia observed by Rodriguez-Bano, et al. (Period C represents the time period when active MRSA surveillance in patients and healthcare workers were performed in units where there was MRSA transmission. A: Shows no decrease in MSSA bacteremia, B: is the decrease found in MRSA Bacteria.
VA Nursing Homes – 36% decrease in MRSA.

Lexington VA Hospital – 95% decrease in MRSA.

VA Study – Jain, NEJM, Apr. 14, 2011
-- Decrease of 45% in non-ICU Patients.
-- Decrease of 62% in ICU Patients.
“In clean surgery wards, strategy 2 (MRSA screening, contact precautions and decolonisation) was associated with decreasing rates of MRSA clinical cultures (15% monthly decrease, aIRR 0.85, 95% CI 0.74 to 0.97) and MRSA infections (17% monthly decrease, aIRR 0.83, 95% CI 0.69 to 0.99).” Intervention phase ran for 12 months, equating to a 86% to 89% decrease.

“... no evidence that enhanced HH promotion was effective.”
“In surgical wards with relatively low MRSA prevalence, a combination of enhanced standard and MRSA-specific infection control approaches was required to reduce MRSA rates. Implementation of single interventions was not effective, except in clean surgery wards where MRSA screening coupled with contact precautions and decolonisation was associated with significant reductions in MRSA clinical culture and infection rates.”
No Reduction Associated With Surveillance
Prior to surgery over half of the known MRSA carriers were not given antibiotics effective against MRSA and because of delays and emergency intervention, 31% of the carriers were identified as MRSA carriers only after surgery.

Of the patients who developed a MRSA infection and were known carriers prior to surgery, only 66% received prophylaxis against MRSA and almost 60% did not receive optimal decolonization of MRSA prior to surgery.

This study effectively negated Lee, et al. Harbarth, S. was the corresponding author of this study.
“... when contact precautions were specified, gloves were used for a median of 82% of contacts, gowns for 77% of contacts, and hand hygiene after 69% of contacts,”

Admission cultures took 5 days to get back.
“Changes in important metrics: According to www.clinicaltrials.gov, 6 months after the study completion date, the registry’s records for the study were updated by adding a measure for all-pathogen bloodstream infections and eliminating the measures for central line-associated bloodstream infections and MRSA urinary cultures.”

“The all-pathogen bloodstream infection (primarily skin commensal organisms) and nosocomial MRSA clinical culture measures showed a statistically significant improvement over the control.

MRSA bacteremia reduction was not significant.”
Derde et al. (Lancet, 2014), also observed a significant decrease in MRSA acquisitions with improved hand hygiene and unit-wide chlorhexidine decolonization protocols. There was not a significant decrease in vancomycin-resistant Enterococcus or Enterobacteriaceae acquisitions.

There is also concern regarding the promotion of bacterial resistance. Disturbingly, Derde et al. reported a 13% to 14% incidence of MRSA resistance to chlorhexidine.

Combined low-level mupirocin and chlorhexidine resistance significantly increases the risk of persistent MRSA carriage after decolonization therapy. Institutions with widespread use of these agents should monitor for resistance and loss of clinical effectiveness. (Lee AS, Clin Infect Dis. 2011)
The recent observation that MRSA strains carrying the antiseptic resistance genes *qacA/B* can be clinically resistant to chlorhexidine raises a note of caution against its unfettered use. The dissemination of chlorhexidine-resistant MRSA would have implications for the decolonization of individual patients and for preventing transmission.

Chlorhexidine Resistance

First reported cases of bacterial resistance against key antibiotics

Preop MRSA Surveillance

  Found no effect but serious flaws.

  Was a well controlled multi-national study which found a beneficial effect. Harbarth, S was the corresponding author of this study.

- Multiple other studies most of which did not control for secular trends also found a beneficial effect.
Preop MRSA Surveillance

- MRSA Carriers Have a Higher Risk for Developing MRSA Infections.
- Screening determines the length of preoperative decolonization. (One vs. five days of chlorhexidine.)
- Type of Antibiotic Used Pre-Op May Depend Upon Carrier State.
The United Kingdom’s National Health Service’s best practices include MRSA screening of:

- Orthopaedics, cardiothoracic and neurosurgical patients;
- Emergency orthopaedic and trauma admissions;
- Critical care admissions;
- All elective surgical patients;
- Previous MRSA carriers;
- Oncology/chemotherapy patients;
- Renal patients;
- Patients admitted from high risks settings such as nursing homes and care homes and;
- All emergency admissions.
“... the logical conclusion of risk factor assessments and the results of modelling studies is that the most appropriate approach to the reduction in MRSA carriage in the population, and resultant MRSA infections, is the universal screening of all admissions to hospital.”


Comparison between trend reductions in MRSA bacteraemias and MRSA acquisitions at a single UK hospital.


© The Author 2011. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org